1. Home
  2. LGND vs ENS Comparison

LGND vs ENS Comparison

Compare LGND & ENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • ENS
  • Stock Information
  • Founded
  • LGND 1987
  • ENS 1991
  • Country
  • LGND United States
  • ENS United States
  • Employees
  • LGND 68
  • ENS N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • ENS Industrial Machinery/Components
  • Sector
  • LGND Health Care
  • ENS Technology
  • Exchange
  • LGND Nasdaq
  • ENS Nasdaq
  • Market Cap
  • LGND 3.2B
  • ENS 3.4B
  • IPO Year
  • LGND 1992
  • ENS N/A
  • Fundamental
  • Price
  • LGND $205.69
  • ENS $144.19
  • Analyst Decision
  • LGND Strong Buy
  • ENS Strong Buy
  • Analyst Count
  • LGND 8
  • ENS 2
  • Target Price
  • LGND $144.71
  • ENS $117.50
  • AVG Volume (30 Days)
  • LGND 139.7K
  • ENS 552.2K
  • Earning Date
  • LGND 08-05-2025
  • ENS 11-05-2025
  • Dividend Yield
  • LGND N/A
  • ENS 0.73%
  • EPS Growth
  • LGND N/A
  • ENS 21.73
  • EPS
  • LGND N/A
  • ENS 8.58
  • Revenue
  • LGND $181,488,000.00
  • ENS $3,725,304,000.00
  • Revenue This Year
  • LGND $18.41
  • ENS $2.83
  • Revenue Next Year
  • LGND $18.87
  • ENS $3.01
  • P/E Ratio
  • LGND N/A
  • ENS $16.81
  • Revenue Growth
  • LGND 53.40
  • ENS 6.17
  • 52 Week Low
  • LGND $81.74
  • ENS $76.57
  • 52 Week High
  • LGND $129.90
  • ENS $144.58
  • Technical
  • Relative Strength Index (RSI)
  • LGND 59.63
  • ENS 70.82
  • Support Level
  • LGND $198.82
  • ENS $132.16
  • Resistance Level
  • LGND $209.10
  • ENS $142.33
  • Average True Range (ATR)
  • LGND 7.14
  • ENS 4.99
  • MACD
  • LGND -0.67
  • ENS 0.27
  • Stochastic Oscillator
  • LGND 53.60
  • ENS 98.22

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About ENS EnerSys

EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.

Share on Social Networks: